Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119105 · ClinicalTrials.gov registry record · Phase 2
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
A Phase 2 study, sponsored by Nabriva Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT01119105 is a Phase 2 study that has completed, run by Nabriva Therapeutics. The registered enrollment target is 210 participants.
The verdict
NCT01119105, a Phase 2 study, has completed, sponsored by Nabriva Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.
Interventions
- DRUG Vancomycin
- DRUG BC-3781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119105
The ClinicalTrials.gov registry entry for NCT01119105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabriva Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT01119105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119105 about?
NCT01119105 is a clinical study titled "Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)". This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.
What is the current status of trial NCT01119105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2010-05. Estimated completion is 2011-02-03.
What interventions are being tested in trial NCT01119105?
The interventions under investigation include: Vancomycin (DRUG), BC-3781 (DRUG).
Who is sponsoring clinical trial NCT01119105?
This trial is sponsored by Nabriva Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.